Considering the advantages that exosomes confer as a therapeutic platform for drug targeted delivery along with the constantly rising associations of EPH/ephrins with a variety of diseases ranging from pathological processes to cancer, this makes them an attracting therapeutic approach. This evidence concerns the gene EPHA1 and cancer.